Medscape

Losartan not OPTIMAAL treatment post-MI

Berlin, Germany - The angiotensin II antagonist losartan (Cozaar®, Merck) failed to show benefits over the ACE-inhibitor captopril in the Optimal Trial in Myocardial Infarction with the Angiotensin II ...
Nasdaq

Scienture Holdings, Inc. Announces FDA Patent Listing for Arbli™, First FDA-Approved Liquid Losartan Formulation

Scienture Holdings announces FDA listing of two patents for Arbli™, the first liquid losartan formulation approved in the U.S. market. Scienture Holdings, Inc. announced that the U.S. FDA has listed ...
Nasdaq

FDA Approves ArbliTM, the First Ready-to-Use Oral Liquid Formulation of Losartan, from Scienture Holdings, Inc.

Scienture Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its liquid formulation of losartan, branded as ArbliTM (losartan potassium) Oral Suspension, at a ...